| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
84,190,000 |
| Market
Cap: |
11.09(B) |
| Last
Volume: |
427,350 |
Avg
Vol: |
426,168 |
| 52
Week Range: |
$67.31 - $157.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 983 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
143,757 |
247,027 |
| Total Buy Value |
$0 |
$0 |
$13,295,068 |
$24,257,422 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
5 |
7 |
| Total Shares Sold |
27,731 |
27,731 |
42,731 |
43,589 |
| Total Sell Value |
$3,499,041 |
$3,499,041 |
$5,099,841 |
$5,194,152 |
| Total People Sold |
7 |
7 |
7 |
7 |
| Total Sell Transactions |
7 |
7 |
8 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2018-10-24 |
4 |
AS |
$127.74 |
$13,735,116 |
D/D |
(107,524) |
20,661 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2018-10-24 |
4 |
OE |
$13.71 |
$1,330,389 |
D/D |
89,400 |
128,185 |
|
- |
|
| Ingram Douglas S |
President & CEO |
• • – |
2018-08-15 |
4 |
B |
$125.26 |
$2,004,211 |
D/D |
16,000 |
399,250 |
2.81 |
- |
|
| Cumbo Alexander |
SVP, Chief Commercial Officer |
• – – |
2018-08-08 |
4 |
D |
$121.02 |
$726,120 |
D/D |
(6,000) |
22,766 |
|
- |
|
| Howton David T |
SVP, General Counsel |
• – – |
2018-08-08 |
4 |
D |
$121.02 |
$822,936 |
D/D |
(6,800) |
28,071 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2018-08-08 |
4 |
D |
$121.02 |
$1,028,791 |
D/D |
(8,501) |
38,785 |
|
- |
|
| Howton David T |
SVP, General Counsel |
• – – |
2018-07-16 |
4 |
AS |
$136.46 |
$6,823,000 |
D/D |
(50,000) |
34,871 |
|
- |
|
| Howton David T |
SVP, General Counsel |
• – – |
2018-07-16 |
4 |
OE |
$13.71 |
$692,691 |
D/D |
50,000 |
72,719 |
|
- |
|
| Cumbo Alexander |
SVP, Chief Commercial Officer |
• – – |
2018-07-09 |
4 |
AS |
$137.32 |
$4,638,944 |
D/D |
(33,782) |
28,766 |
|
- |
|
| Cumbo Alexander |
SVP, Chief Commercial Officer |
• – – |
2018-07-09 |
4 |
OE |
$13.71 |
$465,415 |
D/D |
33,782 |
40,680 |
|
- |
|
| Barry Richard |
Director |
– • – |
2018-06-27 |
4 |
AS |
$130.34 |
$9,775,500 |
D/D |
(75,000) |
3,170,432 |
|
- |
|
| Ingram Douglas S |
President & CEO |
• • – |
2018-06-26 |
4 |
D |
$135.53 |
$5,007,291 |
D/D |
(36,946) |
383,250 |
|
- |
|
| Cumbo Alexander |
SVP, Chief Commercial Officer |
• – – |
2018-05-22 |
4 |
D |
$89.22 |
$128,031 |
D/D |
(1,435) |
28,766 |
|
- |
|
| Cumbo Alexander |
SVP, Chief Commercial Officer |
• – – |
2018-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,876 |
30,201 |
|
- |
|
| Howton David T |
SVP, General Counsel |
• – – |
2018-05-22 |
4 |
D |
$89.22 |
$139,719 |
D/D |
(1,566) |
34,871 |
|
- |
|
| Howton David T |
SVP, General Counsel |
• – – |
2018-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,319 |
36,437 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2018-05-22 |
4 |
D |
$89.22 |
$180,581 |
D/D |
(2,024) |
47,286 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2018-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,649 |
49,310 |
|
- |
|
| Ruff Shamim |
SVP, Chief Regulatory Affairs |
• – – |
2018-05-22 |
4 |
D |
$89.22 |
$116,432 |
D/D |
(1,305) |
31,936 |
|
- |
|
| Ruff Shamim |
SVP, Chief Regulatory Affairs |
• – – |
2018-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,432 |
33,241 |
|
- |
|
| Cumbo Alexander |
SVP, Chief Commercial Officer |
• – – |
2018-03-15 |
4 |
D |
$81.22 |
$51,412 |
D/D |
(633) |
25,325 |
|
- |
|
| Cumbo Alexander |
SVP, Chief Commercial Officer |
• – – |
2018-03-15 |
4 |
OE |
$13.71 |
$51,600 |
D/D |
2,500 |
25,767 |
|
- |
|
| Howton David T |
SVP, General Counsel |
• – – |
2018-03-15 |
4 |
D |
$81.22 |
$55,230 |
D/D |
(680) |
31,118 |
|
- |
|
| Howton David T |
SVP, General Counsel |
• – – |
2018-03-15 |
4 |
OE |
$13.71 |
$55,382 |
D/D |
2,500 |
31,727 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2018-03-15 |
4 |
D |
$81.22 |
$59,615 |
D/D |
(734) |
42,661 |
|
- |
|
360 Records found
|
|
Page 10 of 15 |
|
|
0.12 (0.09%) 
